Genmab — Januar 2020
-
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma https://clinicaltrials.gov/ct2/show/NCT03937635
-
Sidst sagde han således: vi afventer ivrigt de kliniske data fra den igangværende undersøgelse (Isatuximab in combination with Atezolizumab in a number of solid tumors) før vi bestemmer de næste trin for Dara i potentiel behandling af faste kræftformer. Altså underforstået at man overvejer at starte op igen.
-
I Checkmate358 er rekruttering stoppet i dara-armen. Andre dele af studiet kører videre. Checkmate142 (tyktarmskræft) rekrutterer ikke længere, men studiet er aktivt. Resultater nok ikke før 2022. Det "rene" dara-nivo studie i diverse solide rekrutterer heller ikke, men er aktivt. Resultater måske til august. Dette er det eneste studie, hvor der kunne tænkes at være en lille dør på klem til snarlige resultater.
-
God morgen.
-
Tusinde tak Vitus.
-
E L. Thank you. I don't understand the technical terms in all of this, so once in a while I need an explanation. Based on the chat not being full of new comments, I wondered if the solids were really back, hence the question
-
I don't exactly find it easy either @Plimsoller...
On solids; was was said below is correct, but i still think there is a chance it will be revisited once SC is approved
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind